Stockscreener 앱 받기
4.32
0.23%
-0.010
시장 영업 전:
4.33
0.010
+0.23%
전일 마감가:
$4.33
열려 있는:
$4.3
하루 거래량:
5.00M
Relative Volume:
0.88
시가총액:
$1.59B
수익:
$4.09M
순이익/손실:
$-660.15M
주가수익비율:
-1.8739
EPS:
-2.3053
순현금흐름:
$-117.10M
1주 성능:
+7.60%
1개월 성능:
-8.28%
6개월 성능:
+13.68%
1년 성능:
+113.86%
1일 변동 폭
$4.30
$4.505
1주일 범위
$3.92
$4.505
52주 변동 폭
$1.91
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
명칭
Ataibeckley Inc
전화
1 929 207 2670
주소
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
4.32 | 1.59B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Deutsche Bank | Buy |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-07-29 | 개시 | Oppenheimer | Outperform |
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Ataibeckley Inc 주식(ATAI)의 최신 뉴스
AtaiBeckley Inc. Cash Flow – HAM:B72 - TradingView
Total debt of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Balance Sheet – HAM:B72 - TradingView
AtaiBeckley Inc. Trade Ideas — HAM:B72 - TradingView
AtaiBeckley (ATAI) Reports Q1 Financial Results - Insider Monkey
10 Best Penny Stocks to Buy for Long Term - Insider Monkey
These stocks are today’s movers: Fermi, AST SpaceMobile, Intel, Marvell, USA Rare Earth, Ataibeckley, and more - MSN
AtaiBeckley Inc. (NASDAQ: ATAI): Advancing Psychedelic Mental Health Therapies with Clinical Momentum - Kalkine
How AtaiBeckley’s Wider Q1 Loss But Lower Per-Share Hit At AtaiBeckley (ATAI) Has Changed Its Investment Story - simplywall.st
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - marketscreener.com
A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal Differ - Yahoo Finance
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Psychedelic: Compass Pathways, AtaiBeckley, GH Research report earnings - TipRanks
H.C. Wainwright Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $25 - Moomoo
ATAI Technical Analysis | Trend, Signals & Chart Patterns | ATAIBECKLEY INC (NASDAQ:ATAI) - ChartMill
TD Cowen Maintains AtaiBeckley(ATAI.US) With Buy Rating - Moomoo
AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says - Yahoo! Finance Canada
CCORF Maintains AtaiBeckley(ATAI.US) With Buy Rating, Maintains Target Price $15 - Moomoo
ATAI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Needham Maintains AtaiBeckley(ATAI.US) With Buy Rating, Raises Target Price to $15 - Moomoo
Psychedelic stocks soar as Trump signs order to ease access - MSN
AtaiBeckley Inc. 1Q 2026: Revenue $954K, EPS $(0.08) — 10-Q Summary - TradingView
Q1 2026 loss rises at AtaiBeckley (Nasdaq: ATAI); cash and securities detailed - Stock Titan
Small cap wrap: AtaiBeckley, Standard Uranium, 374Water, Nextsource Materials… - Proactive financial news
AtaiBeckley Reports Q1 2026 Results, Initiates BPL-003 Phase 3 for Depression, Projects Cash Runway Into 2029 - Minichart
ATAI Beckley earnings beat by $0.02, revenue topped estimates - Investing.com
AtaiBeckley Q1 Net Loss Narrows, Revenue Declines - Moomoo
AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update - Investing News Network
AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances - Yahoo Finance
Earnings Flash (ATAI) AtaiBeckley Posts Q1 Net Loss $0.08 a Share, vs. FactSet Est of $0.10 Loss - marketscreener.com
AtaiBeckley (NASDAQ: ATAI) details Q1 2026 loss and $209.9M cash runway - Stock Titan
Earnings Flash (ATAI) AtaiBeckley Posts Q1 Net Loss $0.08 a Share, Vs. FactSet Est of $0.10 Loss - Moomoo
Earnings Flash (ATAI) AtaiBeckley Inc. Reports Q1 Revenue $954,000, vs. FactSet Est of $130,000 - marketscreener.com
Earnings Flash (ATAI) AtaiBeckley Inc. Reports Q1 Revenue $954,000, Vs. FactSet Est of $130,000 - Moomoo
AtaiBeckley Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
How Positive Phase 2a Data For EMP-01 In Social Anxiety Disorder At AtaiBeckley (ATAI) Has Changed Its Investment Story - Sahm
AtaiBeckley (ATAI) Reports Positive Phase 2a Results for Social Anxiety Treatment EMP-01 - Insider Monkey
Number of shareholders of AtaiBeckley Inc. – XETR:B72 - TradingView
5 Best Fast Growing Penny Stocks to Buy Right Now - Insider Monkey
AtaiBeckley Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
AtaiBeckley Inc. (ATAI) Stock Analysis: Unveiling a Potential 249% Upside in the Biotech Sector - DirectorsTalk Interviews
ATAI stock soars on track for best day on Trump psychedelics push and Wall Street cheers - MSN
AtaiBeckley Is Said to Explore Options for Main Psychedelic Drug - MSN
Is AtaiBeckley (ATAI) Redefining Its Psychedelic Strategy With Standalone EMP-01 Anxiety Data? - simplywall.st
10 Health Care Stocks With Whale Alerts In Today's SessionAbbVie (NYSE:ABBV), AtaiBeckley (NASDAQ:ATAI - Benzinga
Does AtaiBeckley’s (ATAI) EMP-01 Data Hint At A Scalable MDMA Therapy Platform? - Yahoo Finance
Ataibeckley: Anxiety drug cuts social phobia symptoms by 38% - MSN
Ataibeckley Inc (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):